Plain-English translation of NCT06319196 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Clear-Me is testing whether a combination immunotherapy called BMS986213 (which uses two types of immune-boosting drugs working together) is better than a single immune drug called at preventing melanoma from returning in patients with high-risk disease after surgery. The study focuses on patients whose blood tests show signs of remaining cancer cells, even after the tumor has been surgically removed. This medication combination is designed to wake up your immune system more powerfully to find and destroy any leftover cancer cells.
Even after surgery to remove melanoma, some patients have tiny cancer cells remaining in their blood that can lead to the cancer returning. This trial is testing whether using two immune-boosting drugs together is more effective than using just one at stopping this from happening.
You likely qualify if…
You likely don't qualify if…
You will first have blood drawn to check for cancer DNA; if detected, you'll be randomly assigned to receive either the two-drug combination or the single-drug treatment as an infusion. You'll visit the clinic regularly for treatment and monitoring appointments over several months, with blood tests and imaging scans to track how you're doing. The study expects to follow you for at least a year to see whether the medication helps prevent your melanoma from returning.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
Canada